Clinical trials: Placebo Response
Asthma
A Study in Asthmatics to Determine the Efficacy and Dose Response of Repeat Doses of GW870086X on Forced Expiratory Volume in 1 Second (FEV1)
This is a randomised, double-blind, placebo-controlled, parallel group study to determine the efficacy of twenty-seven day- repeat inhaled daily doses of GW870086X on forced expiratory volume in 1 second (FEV1).
- Trial name
- NCT01245426
- Testing
- GW870086 2mg, GW870086 4mg, GW870086 1mg
- Where
- 11 sites in Bulgaria, Germany and 1 more
- Volunteers
- 136 people
- Sponsor
- GlaxoSmithKline
Arthritis, Rheumatoid
Investigating Clinical Efficacy of Ofatumumab in Adult Rheumatoid Arthritis (RA) Patients Who Had an Inadequate Response to TNF-α Antagonist Therapy
This is a phase III, double-blind, randomized, multicenter, and parallel group trial with a duration of 24 weeks, followed by a 120 week Open-label Period.
- Trial name
- NCT00603525
- Testing
- Ofatumumab
- Where
- 60 sites in Argentina, Denmark and 10 more
- Volunteers
- 169 people
- Sponsor
- GlaxoSmithKline
Rheumatoid Arthritis
A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
Study is a double-blind, randomized, placebo controlled, dose escalating study. The primary objective of this study is to evaluate the safety, tolerability and feasibility of a single intravenous infusion of allogeneic…
- Trial name
- NCT01851070
- Testing
- Allogeneic Mesenchymal Precursor Cells, Normal Saline
- Where
- 23 sites in United States, Australia
- Volunteers
- 48 people
- Sponsor
- Mesoblast, Ltd.
Anthocyanins
Intestinal Inflammatory and Metabolic Responses to a High Fat Meal and Plant Polyphenol Blend
This study will investigate the beneficial effects of supplementation with a plant polyphenol blend rich in anthocyanins on parameters of inflammation and metabolic responses following a challenge with a high-fat (HF) meal.
- Trial name
- NCT03309982
- Testing
- Plant polyphenol blend
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Pharmanex
Depressive Disorder, Major
AndroGel in Men With Major Depression and Incomplete Response to Antidepressant Treatment
We hypothesize that AndroGel may offer some relief to subjects with low or borderline testosterone levels who suffer from depression and have failed to respond to a trial of a standard antidepressant.
- Trial name
- NCT00304746
- Testing
- Testosterone gel
- Where
- 2 sites in United States, Israel
- Volunteers
- 100 people
- Sponsor
- Mclean Hospital
Primary Biliary Cholangitis
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary Cholangitis
A randomized, double-blind study to assess the safety, tolerability, PK and efficacy of EDP-305 in subjects with primary biliary cholangitis
- Trial name
- NCT03394924
- Testing
- EDP-305 1 mg, EDP-305 2.5 mg
- Where
- 86 sites in United States, Australia and 8 more
- Volunteers
- 68 people
- Sponsor
- Enanta Pharmaceuticals, Inc
HIV Infections
The Safety and Effectiveness of PMPA Prodrug in HIV-Infected Patients
To evaluate the safety of single and multiple doses (28 daily doses) of 9-[2-(R)-[[bis[[(isopropoxycarbonyl)- oxy]methoxy]phosphinoyl]methoxy]propyl]adenine fumarate (PMPA) prodrug administered orally to HIV-infected patients.
- Trial name
- NCT00002396
- Testing
- Tenofovir disoproxil fumarate
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- Gilead Sciences
Chronic Obstructive Pulmonary Disease
A Trial to Assess the Pharmacodynamic Response in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
This is a randomized, double-blind, multi-dose, parallel group trial which will assess the pharmacodynamic response of fluticasone propionate and formoterol fumarate in subjects with COPD.
- Trial name
- NCT01168310
- Testing
- Fluticasone Propionate/Formoterol Fumarate, Formoterol Fumarate
- Where
- 23 sites in United States
- Volunteers
- 468 people
- Sponsor
- Dey
Arthritis, Rheumatoid
A Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis Subjects Who Have Had an Inadequate Response to Methotrexate
The purpose of this study is to evaluate the safety and efficacy of ASP015K in moderate to severe rheumatoid arthritis subjects who are methotrexate-inadequate responders (MTX-IR).
- Trial name
- NCT01554696
- Testing
- peficitinib, methotrexate
- Where
- 49 sites in United States, Belgium and 6 more
- Volunteers
- 379 people
- Sponsor
- Astellas Pharma Inc
Etomidate Overdose of Undetermined Intent
A Dose-response Study of Lidocaine and Etomidate
IV lidocaine administration can reduce the minimal amount of Etomidate and time for induction of anesthesia.
- Trial name
- NCT01916642
- Testing
- Lidocaine 1mg/kg, Lidocaine 1.5mg/kg, Lidocaine 2mg/kg
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- West China Hospital
Central Diabetes Insipidus
Plasma Oxytocin Changes in Response to Low-dose MDMA vs. Placebo in Patients With Arginine Vasopressin Deficiency and Healthy Controls
The investigator hypothesize that low-dose MDMA (3,4-methylenedioxymethamphetamine) will produce a sufficiently strong oxytocin stimulation in healthy controls and no relevant increase in patients.
- Trial name
- OxyMAX (NCT06789705)
- Testing
- MDMA
- Where
- Switzerland
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Sepsis, Bacterial Infections and Mycoses
A Study in Sepsis Patients With Renal Failure
The purpose of this study is to investigate the safety and tolerability of AP in sepsis patients with renal failure and to investigate the effect of AP on inflammatory and clinical parameters in sepsis patients with renal failure.
- Trial name
- NCT00511186
- Testing
- BIAP
- Where
- 9 sites in Belgium, Netherlands
- Volunteers
- 36 people
- Sponsor
- AM-Pharma
Allergic Rhinitis
Topical Allstate and Nasal Allergen Challenge
The purpose of this study is to see whether Allstate Nasal Spray when given in the nose is safe and can reduce the signs and symptoms of allergic rhinitis (hayfever).
- Trial name
- NCT01231724
- Testing
- Allstate Nasal Spray
- Where
- United States
- Sponsor
- University of Chicago
Rheumatoid Arthritis
Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate
The primary objective of this study is to evaluate the effects of filgotinib versus placebo for the treatment of signs and symptoms of rheumatoid arthritis (RA) as measured by the percentage of participants achieving an American…
- Trial name
- FINCH 1 (NCT02889796)
- Testing
- Filgotinib, Adalimumab, MTX
- Where
- 230 sites in United States, Argentina and 28 more
- Volunteers
- 1,759 people
- Sponsor
- Gilead Sciences
Asthma
Effect of the GSK2245035 on the Allergen-induced Asthmatic Response
This study will assess whether Toll like receptor 7 (TLR7)-mediated pharmacology, with intranasal (i.n.) GSK2245035 20 nanogram (ng) administered weekly for a period of 8 weeks, will lead to reduced allergic reactivity in the…
- Trial name
- NCT02833974
- Testing
- GSK2245035 Nasal Spray Solution
- Where
- 6 sites in Germany, United Kingdom
- Volunteers
- 36 people
- Sponsor
- GlaxoSmithKline
Post-aggressive Immunosuppression, Adult Patients Admitted to Intensive Care With Initial Severity (SOFA of the First 24 Hours Post-admission ≥ 6
Effect of Interferon Gamma as a Treatment for Post-aggressive Immunosuppression in Intensive Care Units, a Randomized Bayesian Double-blind Controlled Trial Versus Placebo
The vast majority of serious clinical situations leading to intensive care (septic shock, polytrauma, acute cerebral aggression, major surgery) are characterized by significant systemic inflammation.
- Conditions
- Post-aggressive Immunosuppression, Adult Patients Admitted to Intensive Care With Initial Severity (SOFA of the First 24 Hours Post-admission ≥ 6, Adult Under Mechanical Ventilation, and Presenting an mHLA-DR Less Than 8,000AB/C
- Trial name
- INFINITY (NCT06694740)
- Testing
- Interferon Gamma 1-b
- Where
- 2 sites in France
- Volunteers
- 170 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Candidemia, Invasive Candidiasis
Shortening Treatment Duration in Uncomplicated Candidemia: the CanTEN Trial
CanTEN is a multicenter, randomized, double-blind, placebo-controlled, adaptive, non-inferiority phase 4 trial investigating a shortened treatment duration in patients with uncomplicated candidemia.
- Trial name
- CanTEN (NCT07788586)
- Testing
- Caspofungin only within the study, Caspofungin for 3 days within the study
- Where
- 24 sites in Germany
- Volunteers
- 420 people
- Sponsor
- Oliver Cornely, MD
Chronic Obstructive Pulmonary Disease (COPD)
Evaluation of the Efficacy and Safety of MV130 in Chronic Obstructive Pulmonary Disease (COPD)
The goal of this clinical trial is to learn whether the bacterial vaccine MV130 helps reduce the number of exacerbations in adults with moderate to severe COPD. It will also assess the safety and immune effects of MV130.
- Trial name
- MV130 (NCT01842360)
- Testing
- MV130
- Where
- 7 sites in Spain
- Volunteers
- 198 people
- Sponsor
- Inmunotek S.L.
COVID-19
Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib in the treatment of participants with COVID-19-associated Acute Respiratory Distress Syndrome (ARDS) who require mechanical ventilation.
- Trial name
- NCT04377620
- Testing
- Ruxolitinib
- Where
- 36 sites in United States, Russia
- Volunteers
- 211 people
- Sponsor
- Incyte Corporation
Healthy Volunteers
A Study to Investigate the Impact of Dose and Dosing Frequency of AZD8848 on the Response on Biomarkers
The study will investigate how the dose of AZD8848 and the dosing frequency will affect the immunological/inflammatory response by measuring the production of biomarkers in blood and nasal lavage.
- Trial name
- NCT01203124
- Testing
- AZD8848
- Where
- Sweden
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.